Axol Bioscience Ltd.

Axol Bioscience is at the 5th Annual Dry AMD and GA Therapeutics Summit, flying the flag for human iPSCs. We are at the 5th Annual Dry AMD and GA Therapeutics Summit and are proud to be an Exhibition partner at this year's event. As you may have already seen, Phenocell recently joined the Axol Bioscience family. This enables Axol to extend the existing product portfolio into ophthalmology, by offering iPSC-derived Retinal Pigment Epithelial (RPE) cells and high-throughput screening services for dry AMD research and drug testing. Our presence at important events like these shows the great value we place on collaboration by meeting with existing partners and fostering new relationships with future collaborators. Attending this meeting also enables us to keep abreast of new developments and present our progress to the Dry AMD community. Our team is at Booth #1, ready to share how we're supporting the drug discovery market for Dry AMD. Dr. Florian Regent will be presenting a poster showing some of our work in the field: Harnessing the Potential of Induced Pluripotent Stem Cells to Accelerate Drug Discovery for Age-Related Macular Degeneration Our CEO Liam Taylor and Head of Ophthalmology Dr. @Florian Regent are in attendance. Come and talk to us if you are interested in hearing about how you can fuel your in vitro dry AMD models with our iPSC-derived RPE cells, to build a robust and relevant tool for your drug screening campaigns and Hit/Lead validation. Alternatively, you can also email us at operations@axolbio.com. #DryAMD #RPEcells

Phenocell joining the Axol Bioscience family is not just a story of an acquisition but one about uniting people and innovation for greater impact. We are thrilled to have announced our recent acquisition of Phenocell, a strategic move that significantly expands both of our product portfolios and reinforces our joint commitment to building better human models of disease using iPSCs. This partnership goes beyond just adding new products and services; it’s about uniting two teams that share a vision for advancing the development of better human disease models across multiple disease areas. One of the key reasons for this acquisition is the talented scientific team at Phenocell and their commitment to delivering high-quality science. By bringing together our expertise, we can accelerate innovation and drive meaningful advancements in our field. We are also highly aligned in our values and this shared commitment of these values of Performance, Accountability, Transparency, Acting with Integrity, Diversity and Inclusivity and Collaboration will enhance our collaborative efforts and drive innovation forward. Moreover, this acquisition demonstrates our values in action even further as highlighted below: • Performance: Through combining our innovative capabilities in the neuroscience, pain and touch, cardiovascular, ophthalmology and dermatology areas with, we are enhancing our ability to deliver high-quality solutions more effectively. • Accountability: We take responsibility for this strategic decision, ensuring that our collaboration meets the highest standards and delivers value to our community. • Transparency: Throughout the process, we have been committed to maintaining open lines of communication, fostering trust and clarity. • Acting with Integrity: This acquisition reflects our commitment to ethical practices, ensuring that our partnership aligns with our principles and mission. • Diversity and Inclusivity: We recognize the unique strengths of the Phenocell team and this acquisition shows our dedication to creating an inclusive environment where diverse perspectives drive innovation. • Collaboration: This partnership represents a collaborative effort to combine our talents and resources, working together towards shared goals that benefit our customers and the broader community.. Together, we are able to drive innovation and deliver even greater value to our customers and stakeholders. This acquisition marks a significant step forward, enhancing our ability to meet the evolving needs of the market. We look forward to leveraging our combined strengths and working together with urgency to support the industry in developing better human models of disease using iPSCs. If you have any questions concerning this acquisition or about our new products and services, contact us at operations@axolbio.com. #collaboration #humaniPSCs #AcquisitionNews #DrugDiscovery

It's #techtuesday and as always we are here to help you, our community, with any technical questions you may have. At Axol, we've spent more than a decade at the forefront of iPSC technology, developing expertise in using iPSC-derived cells for drug discovery and research. Our straightforward workflows and simple to read protocols ensure you get the best from your cells, and we are always on hand to support you in achieving your goals. In order to provide more support we have ran dedicated Tech Help Clinics to create another means by which our community can get the help they need. So, if you are wondering if we have some specific data about cells, what co-culture studies we have done or how long our cells can be cultured, take a look at one of our Tech Help Clinics related to the topic you are after. These clinics are titled: • iPSC Tech Help Clinic: Human iPSC Derived Sensory Neurons [presented by Dr. Stuart Prime] • iPSC Tech Help Clinic: Human iPSC Derived Cardiomyocytes [presented by Dr Jamie Bhagwan] • iPSC Tech Help Clinic Microglial Cells [presented by Dr. Jessica Tilman] To watch any of these Tech Clinics, visit https://hubs.la/Q02W6mTy0. Don't hesitate to contact us if you have any further questions operations@axolbio.com. #iPSCs #DrugDiscovery #StemCells #biopharma #techtuesday

Fuel your in vitro dry AMD models with our iPSC-derived RPE cells Age-related macular degeneration (AMD) is a leading cause of blindness worldwide, and the therapeutic options for dry-AMD, the most common form accounting for 80-90% of cases, remain limited. A major challenge in developing effective treatments is the absence of reliable in vitro AMD models, which has slowed drug discovery efforts. The retinal pigment epithelium (RPE) is the cell type primarily affected in AMD. While primary and immortalized RPE lines have provided valuable insights into RPE functions under normal and pathological conditions, they exhibit limitations for drug discovery. To address this pressing need for dry AMD therapies, we at Axol are doing our part in developing faithful in vitro dry AMD models through the production of functionally relevant RPE cells. We have extensively characterized our iPSC-derived RPE cells for phenotypic and functional relevance. Key highlights include: • Expression of key markers (MITF, ZO-1, PMEL17) by immunostaining • Typical pigmented and cobblestone morphology • High purity, with >95% PMEL 17 expression on flow cytometry • Outer retinal barrier resistance measured via volt/ohm meter • Functional relevance in phagocytosis assay We’re also applying our extensive technical expertise and operational excellence to offer iPSC products and a range of outsourced services for dry AMD research such as High-throughput screening services. To find out more about our products and services to support drug discovery and research for AMD, download our new brochure here: https://hubs.la/Q02VZj7r0 Contact us at operations@axolbio.com, if you have any questions or for a quotation. #dryAMD #RPECells #iPSCs

We have created the first in vitro model that captures key mechanisms involved in RPE atrophy in age-related macular degeneration using human iPSCs. Age-related macular degeneration (AMD) is a leading cause of blindness worldwide, and the therapeutic options for dry-AMD, the most common form accounting for 80-90% of cases, remain limited. A major challenge in developing effective treatments is the absence of reliable in vitro AMD models, which has slowed drug discovery efforts. The retinal pigment epithelium (RPE) is the cell type primarily affected in AMD. While primary and immortalized RPE lines have provided valuable insights into RPE functions under normal and pathological conditions, they exhibit limitations for drug discovery. In a recent poster titled "Harnessing the potential of induced pluripotent stem cells to accelerate drug discovery for age-related macular degeneration", we at Axol Bioscience sought to establish a highly relevant in vitro AMD model by developing a protocol for the large-scale differentiation of multiple iPSC lines into RPE cells. The cells were then treated with chronic low doses of A2E, and exposed to blue light, simulating lipofuscin accumulation, an aging mechanism implicated in AMD. Our results demonstrated that this combination of stressors induced AMD hallmarks in iPSC-derived RPE cells, including increased oxidative stress, complement pathway activation, increased pro-inflammatory cytokine secretion, and RPE atrophy. As such we have been able to create the first in vitro model that faithfully recapitulates key mechanisms involved in RPE atrophy associated with AMD. Moreover, we collected multiple patient cell lines to be able to account for the impact of genetic backgrounds on the efficacy of potential treatments. Dr. Florian Regent, Head of Ophthalmology at Axol, will be presenting this poster at the 5th Dry AMD & GA Therapeutics Summit, 28-30 October in Boston, USA. If you will be at the Summit, come over to Booth #1 to find out more. Alternatively, you can download our Dry AMD Brochure here https://hubs.la/Q02VQly40 or email us at operations@axolbio.com. #dryAMD #humanIPSCs #iPSCCommunity

iPSC—MEA data alert! Axol has published a new whitepaper showing characterization data of a human iPSC-derived motor neuron disease model for ALS drug discovery using Axion BioSystems' Maestro Pro. We have recently published a new whitepaper where we collaborated with Axion BioSystems by using their Maestro Pro to characterize a human iPSC-derived motor neuron disease model for ALS drug discovery. Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease, characterized by the progressive loss of motor neuron function, of which there is currently no cure. With current treatment aimed mainly at symptomatic relief, there is a need for better treatment options for patients with this debilitating disease. Key to this, is having better in vitro models of ALS that are more translational relevant. At Axol, our work in the iPSC space aims to support the industry's journey towards this through the production of iPSC-derived motor neurons fit for disease modelling. We understand the importance of characterizing these cells to ensure that are functionally relevant. This is essential for establishing reliable disease models, as it ensures that the cells accurately reflect the key pathological features of ALS, such as hyperexcitability. In this whitepaper, we characterized motor neurons morphologically and functionally, via multielectrode array from 4 different lines. The data illustrated in the whitepaper demonstrated how the ALS phenotype lines displayed a reproducible loss of synchronous firing and different degrees of hyperexcitability. This is in accordance with expected ALS clinical pathology and supports the case for the use of these cells in experimental in vitro models to study ALS pathology and potential therapeutics. Read the full whitepaper here: https://hubs.la/Q02VQ2Px0 Learn more about axoCells Motor Neurons: https://hubs.la/Q02VQ0vF0 If you have any questions, contact us at operations@axolbio.com. #iPSCs #MotorNeurons #MEA #ALS

As the ALS research community urgently looks to utilize more relevant and accessible in vitro models, we continue our work to manufacture, characterize, and understand iPSC-derived motor neurons. In our recent launch of the 'axoCells™ ALS Toolbox' we shared manufacturing and characterization data from 6 iPSC-derived motor neurons - including two unaffected donors, one C9orf72 carrying donor (a sibling to one of the ALS donors), and three donors each carrying significant genotypes associated with ALS, SOD1, C9orf72 and TDP43. We have shared production QC data from running each line three times, demonstrating consistency. Importantly, this set allows us to compare lines and measure by ICC, SNA and MEA phenotypes and evaluate hyperexcitability and synchronicity between lines. We will discuss this set and its application to ALS in vitro models on this webinar - register below. About ALS: ALS is the most common form of motor neuron disease, where the progressive destruction of motor neurons leads to loss of muscular functions including walking, talking, swallowing, and breathing. There is currently no cure. With treatment aimed at symptomatic relief and prolonging survival, most patients live only 3-5 years from the onset of symptoms. With limited treatment options and a predicted 69% increase in cases by 2040, attention has turned to in vitro ALS models that use human iPSCs from healthy or ALS patient donors. We with many others are working with urgency toward the development of better, more human in vitro tools to support effective drug discovery. Learn more about axoCells Motor Neurons: https://lnkd.in/eNu3DApi To find out more about our new axoCells ALS toolbox, download our latest ALS brochure by visiting the following link: https://lnkd.in/ep3AJffr For a quotation, contact operations@axolbio.com or one of our authorized distributors. #ProductLaunch #NeurodegenerativeResearch #HumanRelevantModels #Webinar #ScientificCommunity #humaniPSCs #ScientificAdvances

iPSCs: An Alternative for Better Patient Stratification in Neurodegenerative Disease Trials Given the 99.6% failure rate in drug development, our CEO Liam Taylor emphasizes the critical need for innovative strategies. By leveraging iPSCs for patient stratification, we could effectively screen compounds and identify mutations that demonstrate positive responses. This also provides the opportunity to increase the number of iPSC patient lines and thereby minimize the number of patients needed for recruitment in clinical trials. Such would also increase the diversity of the iPSC patient lines to better reflect the population, leading to more accurate and efficient trials. Our commitment in supporting the community by manufacturing high-quality iPSCs under ISO 9001 accredited conditions, consistently and at scale, is essential and is our contribution to revolutionizing this process and enhancing outcomes for patients. Let's continue to make progress and drive real transformative change for neurodegenerative disease patients. To found out more about our iPSCs, view our Catalog here https://lnkd.in/epUnnZWt or alternatively email us at operations@axolbio.com. #IPSCs #research #betterhumandiseasemodels #drugdiscovery #alzheimersdisease #alzheimersresearch

Join us today at 4pm (BST) for our live event "A new set of iPSC-derived motor neurons for ALS drug discovery." presented by Hannah Sharplin. In this live event, we will cover: ·      iPSC-derived models to support ALS drug discovery ·      The development of an 'ALS Toolbox' ·      Our characterization methods of our axoCells in this toolbox and associated results ·      Our next steps We look forward to sharing our work and journey so far in supporting the development of better in vitro models for ALS. It is not too late to register. Learn more about axoCells Motor Neurons: https://lnkd.in/eNu3DApi To find out more about our new axoCells ALS toolbox, download our latest ALS brochure by visiting the following link: https://lnkd.in/ep3AJffr For a quotation, contact operations@axolbio.com or one of our authorized distributors. #ProductLaunch #NeurodegenerativeResearch #HumanRelevantModels #Webinar #ScientificCommunity #humaniPSCs #ScientificAdvances

Axol Bioscience is the first choice for products and services to support drug discovery and research for Age-related Macular Degeneration (AMD). Identify new pharmaceutical active ingredients with our selection of innovative high-throughput bioassays using iPSC-derived retinal pigment epithelial (RPE) cells. Axol’s dry AMD model is based on the use of iPSC-derived RPE cells from multiple donors including cells differentiated from healthy donors, and cells from AMD patients with risk alleles. We have a range of high-throughput bioassays including: ·      growth factor secretion ·       outer retinal barrier resistance ·      phagocytosis ·      immunolabelling ·      oxidative stress ·      cell viability While every project is unique, we utilize established workflows to ensure projects are conducted efficiently with a kick-off meeting, open communication and full data sharing. Learn more: https://lnkd.in/ewHmX5_Y or get in contact with us at operations@axolbio.com #dryAMD #RPECells #iPSCs